TRIM56 is an antiviral host factor against BVDV. The antiviral effect is specific for BVDV as 15 we found TRIM56 had no effect on replication of vesicular stomatitis virus (VSV) and HCV. We 16 report TRIM56 inhibits BVDV propagation by acting on intracellular viral RNA replication. 17
Furthermore, we provide evidence that the antiviral function of TRIM56 depends both on its E3 18 ubiquitin ligase activity and on the integrity of its C-terminal region, but is not attributed to a 19 general augment of IFN response. Our study adds TRIM56 to the list of antiviral TRIMs and 20 provides novel insights in understanding the antiviral mechanisms of TRIM56. Akashi (38). pIRES-V5-TRIM25 (8) and p3XFLAG-Ub (6) were gifts from Jae Jung and Susan 2 Baker, respectively. pcDNA6-mycNpro (WT, L8P and C69A mutants) have been described (5). 3
RNAi. A shRNA construct targeting boTRIM56 (pLKO.1pur-boT56-097shRNA) was 4 constructed in the pLKO.1-TRC cloning vector (Addgene) using the following oligonucleotides, 5 5'-ccggCGCGCGGCTCTATCTCATCAActcgagTTGATGAGATAGAGCCGCGCGtttttg-3' 6 (forward, boTRIM56 sequence in uppercase letters) and 5'-7 aattcaaaaaCGCGCGGCTCTATCTCATCAActcgagTTGATGAGATAGAGCCGCGCG-3' 8 (reverse). The TRIM56 shRNA in pLKO.1puro vector (pLKO.1puro-T56-097shRNA) was 9 purchased from Openbiosystems (TRCN0000073097), in which the TRIM56 target sequence 10 was CGCACGGCTCTATCTCATCAA. To generate the TRIM56 shRNA vector (pRevTRE-11 T56-097shRNA) that allows selection of transfected cells with Hygromycin, the U6 promoter-12 huTRM56 shRNA cDNA cassette was excised from pLKO.1puro-T56-097shRNA by EcoRI 13 (polished to blunt end) and ClaI digestion and ligated into pRevTRE (Clontech) which was 14 digested with XhoI (polished to blunt end) and ClaI. 15
For stable knockdown of boTRIM56, MDBK cells were transfected with linearized 16 pLKO.1pur-boT56-097shRNA vector and selected in medium containing puromycin (5 µg/ml). 17 (Table S1 ). In parallel, only a few polypeptides were purified from control HeLa 20 cells by anti-FLAG IP (Fig. 1B, lane 2) , and none was found to overlap with those proteins co-21 immunoprecipitated with FH-N pro as determined by mass spectrometry (data not shown). Fig. S1 and Fig. 2A) . Thus, TRIM56 belongs to the C-V subfamily of TRIMs (21, 29). 1
To determine which part of TRIM56 mediates its interaction with N pro , we generated an array of 2 human TRIM56 deletion mutants ( Fig. 2A) and determined their abilities to interact with N pro by 3 co-IP (Fig. 2B-C) . We found that deletion of the C-terminal half of TRIM56 (∆369-742, lane 5 4
in Fig. 2B ) abrogated the ability of TRIM56 to interact with N pro , while deletion of RING (lane 3 5
in Fig. 2B) , B-box (lane 4 in Fig. 2B ), or both (lane 4 in Fig. 2C ), or the Coiled-coil domain 6
(lanes 5-6 in Fig. 2C ) failed to do so. To determine which part of the C-terminal sequence of 7 TRIM56 is critical for its association with N pro , we conducted a more fined internal deletion 8 analysis of TRIM56 starting from aa residue 290, producing 6 mutants with each removing 9 approx. 60-90 aa toward the C-terminus ( This suggests TRIM56 promotes ubiquitination of itself. Mutation of the conserved cysteine 3 residues within the RING domain of TRIM56 completely abrogated its ability to induce self-4 ubiquitination (lanes 5-6, Cys 24 to Ala; and lanes 7-8, both Cys 21 and Cys 24 substituted to 5 Ala), confirming that the E3 ubiquitin ligase activity of TRIM56 depends on its RING domain. 6
The TRIM proteins are known to homo-multimerize through their Coiled-coil domains, 7 thereby identifying specific cellular compartments (24). We found that TRIM56-V5 associated 8 with TRIM56-Flag in co-IP experiments, regardless of whether the RING-domain was intact 9
(WT) or mutated (CC21/24AA) ( (Fig. 5B ). In agreement with this, WT TRIM56-expressing MDBK 1 cells consistently had substantially less CPE and better cell survival than did Bsr cells upon 2 infection with cp BVDV NADL at increasing MOIs (Fig. 8C) . These data suggest that TRIM56 3 is an antiviral cellular factor against BVDV infection, and that the anti-BVDV activity of 4 TRIM56 depends on its E3 ligase activity. an increase in luciferase activity over 72 h followed by a plateau later. In contrast, replication of 8 this BVDV RNA was blunted in cells expressing WT TRIM56 (Fig. 6B) . Stable, ectopic 9 expression of boTRIM56 also substantially reduced cellular permissiveness for the BVD39 10 replicon compared with MDBK-Bsr cells (Fig. 6C) , confirming that boTRIM56, like its human 11 homolog, also suppresses BVDV RNA replication when ectopically expressed. By contrast, 12 ectopically expressed TRIM56 (WT, or C24A and C21/24AA mutants) had no demonstrable 13 effect on replication of a genome-length J6/JFH1 HCV RNA replicon encoding renilla luciferase 14 (J6/JFH1-RL, Fig. 6A ) in HCV-permissive Huh7 cells (Fig. 6D) . These results suggest that 15 TRIM56 specifically restricts BVDV infection by targeting an intracellular BVDV RNA 16 replication step. 17
The endogenous bovine TRIM56 restricts BVDV replication. Next, we determined 18 whether the endogenous boTRIM56, expressed at physiological levels, also restricts BVDV 19 replication. We stably transfected MDBK cells with a shRNA construct that targets specifically 20 the boTRIM56. Because neither the commercially available TRIM56 antibodies nor our custom-21 made one could detect the endogenous boTRIM56 protein (data not shown), we utilized realtime 22
RT-PCR to screen MDBK cell clones with efficient knockdown of boTRIM56 mRNA. Two 23 on June 30, 2017 by guest http://jvi.asm.org/ Downloaded from individual clones, designated T56i#2 and T56i#3, respectively, were selected for further analysis 1 because they expressed only ~20% TRIM56 mRNA compared with the parental MDBK cells 2 (Fig. 7A ). Both T56i cell clones responded similarly to SeV infection or transfected poly-I:C in 3 induction of two well-known IFN stimulated genes (ISGs), ISG15 and MxA, when compared 4 with control MDBK cells (Fig. 7B) , indicating that knockdown of TRIM56 did not impair type I 5 IFN response in these cells. We found that both T56i#2 and T56i#3 cells were substantially more 6 permissive than control MDBK cells in supporting the replication of BVD39 replicon, allowing a 7 more earlier, efficient BVDV RNA replication than the latter (Fig. 7C ). Taken together, these 8 data confirms the biological relevance of TRIM56's antiviral activity against BVDV. (Fig. 2) , suggesting this region is critical for TRIM56's ability to interact with viral, and 14 possibly, cellular proteins. We determined whether the C-terminal portion of TRIM56 is also 15 critical for its antiviral function. To this end, we generated MDBK cells stably expressing a 16 mutant TRIM56 lacking the aa 693-750 at the C-terminus (Fig. 8A, lane 5 ). Although its 17 expression level was higher than that of WT TRIM56, this TRIM56 mutant was no longer able to 18 inhibit BVDV propagation (Fig. 8B) or replication of the BVD39 RNA replicon (Fig. 8D) . It also 19 failed to protect cells from BVDV-induced CPE (Fig. 8C) . Since the ∆693-750 mutant also lost 20 its ability to interact with N pro (lane 12 in Fig. 2C ), we wondered whether the TRIM56-N (Fig. 6A, middle panel) . We found that WT TRIM56 still restricted the 1 replication of the BVD39-NS2 replicon, while the ∆693-750 mutant failed to do so (Fig. 8E) . 2
Similarly, we found a TRIM56 mutant lacking aa 621-695 (in which the deletion was close to the 3 C-terminus but upstream of the ∆693-750 deletion) also lost the antiviral activity against the 4 BVD39-NS2 replicon when stably expressed in MDBK cells (Fig. 8F , see lane 4 in Fig. 8A for 5 characterization of its expression). We conclude from these experiments that the C-terminal 6 structural integrity, but not the TRIM56-N pro interaction, is important for the antiviral activity of 7 TRIM56 against BVDV. 8
TRIM56 does not promote the degradation of BVDV NS proteins required for viral 9
RNA replication. Because our data suggested that the E3 ubiquitin ligase activity of TRIM56 10 was required for its antiviral effect against BVDV RNA replication, we considered the 11 possibility that TRIM56 may target one or more BVDV NS proteins required for BVDV RNA 12 replication, for degradation. To test this hypothesis, the individual BVDV NS proteins were 13 ectopically co-expressed with excessive WT or the E3 ligase-deficient CC21/24AA mutant 14 TRIM56 (at a ratio of 1:6) in 293FT cells and their protein abundances were determined by 15 immunoblot analysis (Fig. 9) . We found the BVDV NS2-3, NS3, NS4A, NS4B, NS5A and 16 NS5B proteins were expressed at comparable levels in cells co-expressing WT or the 17 CC21/24AA mutant TRIM56, suggesting that they are not targeted by TRIM56 E3 ligase for 18 degradation. Therefore, other mechanism (s) of action is responsible for the antiviral effect of 19 TRIM56 against BVDV. 20
TRIM56 is a ubiquitous protein whose expression is further up-regulated by IFN or 21
virus infection. To determine the tissue distribution of TRIM56, we assessed the expression of 22 human TRIM56 protein by multiple-tissue western blot (Fig. 10A) . We found that TRIM56 23 on June 30, 2017 by guest http://jvi.asm.org/ Downloaded from protein was expressed ubiquitously in all human tissues examined, including brain, heart, small 1 intestine, kidney, liver, lung, skeletal muscle, stomach, spleen, ovary and testis. In all tissues, 2 TRIM56 was mainly expressed as a protein of approximately 81 kDa, which corresponds to the 3 predicted molecular mass of human TRIM56 (arrow head). Of note, lung and stomach were 4 among the organs with highest expression of TRIM56, while brain expressed the least but 5 nonetheless detectable TRIM56 protein. 6
Many TRIM proteins are transcriptionally regulated by IFNs (3, 23). We found both the 7 mRNA ( Fig. 10B) and protein ( Fig. 10C ) levels of human TRIM56 were moderately upregulated 8 by IFNα (~3 fold). IFN also upregulated boTRIM56 transcripts to similar extent in bovine cells 9 (Fig. 10E, solid bar) . To determine whether TRIM56 is induced by viruses, in particular, BVDV, 10 we studied TRIM56 expression in MDBK cells stably overexpressing Flag-and HA-tandem 11 tagged human IRF3 (BK-IRF3, lanes 1-3 in Fig. 10D ). In BK-F3 cells, IRF3 protein was no 12 longer degraded by N pro following BVDV infection because of its overexpression, allowing cells 13 to mount IFN response to BVDV infection, as evidenced by the induction of bovine ISG15 (Fig.  14   10D, lane 3) . This phenotype, however, was not observed in BK-F3DN133 cells (lanes 4-6 in Fig.  15 10D) that stably overexpressing an IRF3 mutant lacking the N-terminal 133 aa (lane 6). We 16 found that TRIM56 mRNA was induced by 4-and 5.5-fold, upon infection with BVDV and SeV, 17 respectively, in BK-F3 cells (Fig. 10E) . Collectively, the ubiquitous tissue distribution of 18 , 21). In the current study we have identified TRIM56 as a novel player in antiviral innate 5 immunity which acts specifically to inhibit the replication of BVDV, a positive-stranded RNA 6 virus of pestivirus genus within the Flaviviridae family. We demonstrate that TRIM56 possesses 7 RING-dependent E3 ubiquitin ligase activity and self-associates (Fig. 3) , features demonstrated 8 for other TRIM family E3 ligases (18, 24). When ectopically expressed, TRIM56 from either 9 bovine or human species strongly and specifically suppressed BVDV replication (Figs. 5-6) . 10 Importantly, knockdown of endogenous TRIM56 rendered bovine cells substantially more 11 permissive for BVDV replication (Fig. 7) Secondly, although MDBK cells overexpressing TRIM56 were substantially less permissive for 4 BVDV replication than were cells expressing the control vector or the E3 ligase deficient 5 TRIM56 mutants (Fig. 5B and 6B) , no difference was seen among these cells with regards to 6 their ability to support propagation of VSV (Fig. 5C ), a virus routinely used for IFN antiviral 7 activity assays. Thirdly, ectopic expression of TRIM56 or its RING mutants in HCV-permissive 8 Huh7 cells had no appreciable effect on replication of HCV ( Fig. 5E and 6D ), which is sensitive 9
to IFNs' action in cell culture (17), indicating the antiviral activity of TRIM56 is virus-specific. 10
Fourthly, stable knockdown of endogenous boTRIM56 in MDBK cells did not apparently affect 11
SeV-or transfected poly-I:C-induced expression of ISG15 and MxA (Fig. 7B) , suggesting the 12 enhanced permissiveness for BVDV replication in the boTRIM56-knockdown MDBK cells ( (Fig. 7B), indicating  2 there may be cell-type specific differences in the role for TRIM56 in induction of IFN response. 3
Interestingly, MDBK cells failed to upregulate ISG15 and MxA expression following 4 transfection of dsDNA, although they responded robustly to SeV and transfected poly-I:C (Fig.  5   7B) . 6
Our data indicate that TRIM56 targets BVDV propagation by suppressing intracellular 7 viral RNA replication, as it inhibited the replication of subgenomic BVDV RNA replicons that 8 bypass the viral entry and uncoating steps and also do not lead to packaging and release of 9 progeny viruses (due to lack of viral structural genes). However, we can not exclude the 10 possibility that TRIM56 may also act on these early and late steps of BVDV life cycle, as 11 demonstrated for other antiviral TRIMs in restricting retroviruses (20, 21). As in the case of 12 HCV and other flaviviruses, pestiviruses replicate their RNAs on cytoplasmic membranes (25). 13
We found TRIM56 is expressed exclusively in cytoplasm (Fig. 1D) (Fig. 9) , indicating they are not targeted by the TRIM56 E3 ligase for 2 degradation. Whether TRIM56 E3 ligase promotes posttranslational modification(s) of one or 3 more BVDV NS proteins and/or cellular factors to impair BVDV replication will require future 4 investigation. 5
What is the role of the C-terminal region in the antiviral action of TRIM56? Although this 6 portion of TRIM56 has no known domain structures, its integrity is crucial for TRIM56's ability 7 to interact with N pro and also to confer BVDV restriction. However, N pro itself is not essential for 8 BVDV replication (25), and the anti-BVDV activity of TRIM56 does not rely on the TRIM56-9 N pro interaction, since replication of the BVD39-NS2 RNA replicon that does not encode N pro 10 was still blunted upon TRIM56 overexpression (Fig. 8E-F) . Conceivably, the TRIM56 C-11 terminal region may mediate critical protein-protein interactions between TRIM56 and cellular 12 and/or viral proteins that determine viral fitness. Thus far, we have been unable to co-13 immunoprecipitate TRIM56 with BVDV NS2-3, NS3, NS4A, NS4B, NS5A or NS5B (data not 14 shown). Alternatively, the C-terminal part of TRIM56 may bind to BVDV RNA and regulate 15 viral RNA replication directly. Of note, the SPRY domain, which is present in the C-terminal 16 region of many TRIMs (although not in TRIM56), has been proposed to bind RNA (22). 17
Examination of a wide variety of human tissues allowed us to demonstrate the ubiquitous 18 expression of TRIM56 protein (Fig. 10A) (Fig. 10) (3, 33) provide further support for the notion that 2 TRIM56 is an antiviral host factor. 3
What is the biological significance of the N pro -TRIM56 interaction? Interestingly, we 4 reproducibly observed that the protein abundance of TRIM56 was profoundly lower in HeLa-5
FHNpro cells compared with control HeLa cells (Fig. 1A, compare lanes 1 vs. 3 ) and inhibition 6 of the proteasome substantially increased TRIM56 level (compare lanes 1 vs 2) in HeLa-FHNpro 7 cells. This suggests that N pro likely promotes proteasomal degradation of TRIM56, as it does for 8 IRF3. Thus, not only is TRIM25 subjected to viral control (7), but TRIM56-mediated antiviral 9 defense is also targeted for inhibition by virus-encoded proteins, and the degradation of TRIM56 10 by pestivirus N pro represents one such example. 11
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